Innovent Biologics, Inc.
IVBXFOTCHealthcare● Active
$9.10
$-0.99(-9.85%)
Market Cap$15.8B
P/E Ratio—
52W High$15.12
52W Low$9.01
Innovent Biologics, Inc. (IVBXF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · IVBXF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $12.70B | $9.42B | $6.21B | $4.56B | $4.27B |
| Cost of Revenue | $1.71B | $1.51B | $1.81B | $0.93B | $0.57B |
| Gross Profit | $10.99B | $7.91B | $4.40B | $3.63B | $3.70B |
| Gross Margin %(computed) | 86.54% | 83.97% | 70.89% | 79.57% | 86.58% |
| Operating Expenses | |||||
| R&D Expenses | $2.56B | $2.68B | $2.23B | $2.87B | $2.48B |
| G&A Expenses | $0.00B | $0.74B | $0.75B | $0.84B | $0.88B |
| Total Operating Expenses | $9.03B | $7.65B | $6.08B | $6.21B | $5.75B |
| Operating Income | $1.97B | ($0.76B) | ($1.68B) | ($3.12B) | ($2.70B) |
| Operating Margin %(computed) | 15.50% | -8.02% | -27.06% | -68.54% | -63.31% |
| Interest Income | $0.00B | $0.42B | $0.45B | $0.19B | $0.15B |
| Interest Expense | $0.08B | $0.07B | $0.10B | $0.10B | $0.06B |
| Income Before Tax | $0.82B | ($0.08B) | ($1.14B) | ($2.17B) | ($2.64B) |
| Income Tax Expense | $0.02B | $0.02B | ($0.12B) | $0.01B | $0.09B |
| Net Income | $0.79B | ($0.09B) | ($1.03B) | ($2.18B) | ($2.73B) |
| Net Margin %(computed) | 6.24% | -1.00% | -16.56% | -47.83% | -63.91% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.47 | $-0.06 | $-0.66 | $-1.46 | $-1.88 |
| Wtd Avg Shares | 1.68B | 1.58B | 1.56B | 1.49B | 1.45B |
| EBITDA | $1.97B | ($0.48B) | ($0.66B) | ($1.75B) | ($2.37B) |
| EBITDA Margin %(computed) | 15.50% | -5.10% | -10.65% | -38.39% | -55.61% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · CNY · B
Explore more Innovent Biologics, Inc. data
About Innovent Biologics, Inc. (IVBXF) Income Statement
Innovent Biologics, Inc. (IVBXF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, IVBXF reported revenue of $12.70B, gross profit of $10.99B (gross margin 86.54%), and net income of $0.79B — a net profit margin of 6.24%.
Frequently asked questions
IVBXF · 4 questionsInnovent Biologics, Inc. (IVBXF) reported revenue of $12.70B for 2025, up 34.8% year-over-year.
IVBXF revenueIVBXF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09